Image 01 Image 03

FDA Tag

Novavax might give America its fourth COVID-19 vaccine after a trial showed it is 90.4% overall efficient. The vaccine also protects people from moderate and severe COVID-19 in the PREVENT-19 Phase 3 trial.

Pfizer and BioNTech found its COVID-19 is 95% effective in the last trial run, "meeting all primary efficacy endpoints." The vaccine also showed signs of safety and met all the requirements for the FDA to approve its use as soon as possible.

I would like to start today's post with some good news from my day job: My consulting firm is now going forward with the preparation of recommissioning businesses in anticipation of the restart of the economy. Meanwhile, the head of the World Health Organization responded to President Donald Trump, who slammed the agency during a recent Coronavirus Task Force briefing.